Immatics Announced Updated Phase 1B Data On ACTengine IMA203 TCR-T Targeting PRAME In Melanoma Patients And Provided An Update On Upcoming Phase 3 SUPRAME Trial Of IMA203 In Metastatic Melanoma Patients
Portfolio Pulse from Benzinga Newsdesk
Immatics announced updated Phase 1b data for its ACTengine IMA203 targeting PRAME in melanoma patients, showing promising results in progression-free survival and overall survival. The company plans to proceed to a Phase 3 trial, SUPRAME, set to begin in December 2024.
October 10, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immatics announced promising Phase 1b data for IMA203 in melanoma, with a 54% response rate and plans for a Phase 3 trial. This could enhance investor confidence and impact stock positively.
The updated Phase 1b data shows a strong response rate and favorable progression-free survival, which are positive indicators for the upcoming Phase 3 trial. This news is likely to boost investor confidence in Immatics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100